INTRODUCTION
Cisplatin (cis-dichlorodiamineplatinum, CDDP or DDP) is an antineoplastic drug that is often used to treat cancers, including those derived from the head, the neck, and the lung [1] [2] [3] [4] . Using cisplatin alone or in combination with other chemotherapeutics can effectively kill rapidly malignant cells, and has been a routine option for systematic elimination of cancerous cells following surgeries and radiotherapies [5] [6] [7] [8] [9] [10] . The antineoplastic activity of cisplatin is largely attributed to its property to bind to and crosslink DNA, and to inhibit transcription and/or DNA replication, thereby triggering an apoptotic program in the targeted cells [11] [12] [13] [14] . However, there is growing evidence for patients to develop gradually resistance to cisplatin, the concern that has drawn a great attention in clinical practices © Science China Press and Springer-Verlag Berlin Heidelberg 2015
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(TEM), dynamic light scattering (DLS) and light absorption spectrum. We found that the treated cells contained significant amounts of nanoparticle-like substances that share an atomic property with that of elemental platinum. Similar nanoparticles were also formed when cisplatin was mixed with either cell lysates or a series of reducing agents. Also, we demonstrated that Pt particles were unable to compromise the viability of tumor cells. Thus, our data suggest that conversation of cisplatin to nanoparticles by reducing agents contributes to a new mechanism for the progression of cisplatin resistances at a pre-target stage.
RESULTS AND DISCUSSION
Intracellular cisplatin-related particle-like structures
The intracellular fate of cisplatin was examined by using human HEp2 tumor cells, which have a great sensitivity to the drug. TEM revealed that many condensed particles with high contrasts were present in the cytoplasm of the cells treated with cisplatin (Fig. 1a, arrows) . The detection was apparently specific for cisplatin-treated cells because these particles were not found in the cells without cisplatin treatment (Fig. 1b) . Analysis of the lysates prepared from cisplatin-treated cells with TEM also displayed the presence of small particles with an average size less than 5 nm (Fig.  2a) . To determine whether cells contained any substances that were able to induce the formation of these particles from cisplatin, cell lysates were prepared from non-treated cells and incubated with cisplatin for 12 h in vitro prior to TEM analysis. As shown in Fig. 2b , such cisplatin-mixed lysates had also many particles with the sizes similar to those found within the cytoplasm of cisplatin-treated cells. In contrast, no particles were visualized in a cell lysate without added cisplatin (Fig. 2e) . To further confirm the nature of these particles, they were compared with Pt nanoparticles (Pt-NPs) that were prepared by reduction of hexachloroplatinic acid, a soluble platinum chemical, with sodium citrate [31] . These synthetic particles were found to have the sizes and shapes similar to those of the particles found either inside the cisplatin-treated cells or cell lysates mixed with cisplatin (Fig. 2c) . Interestingly, when hexachloroplatinic acids were incubated with cell lysates for 12 h, many particles were also formed though the sizes of these particles appeared smaller than those found in the cells (Fig. 2d) . Taken together, these data indicate that cell lysates were sufficient to trigger the formation of platinum particles from cisplatin, and support the notion that intracellular nanoparticles were produced from the internalized cisplatin.
Identification of the Pt-NPs
It has been reported that Pt-NPs are able to aggregate with proteins, thereby yielding absorptions under ultraviolet (UV) spectrum [32] . Therefore, it is worthwhile to investigate whether the Pt-NPs formed within cells may also cluster intracellular proteins and acquire a specific absorption under UV light. Indeed, cells treated with cisplatin displayed blue fluorescence with an intensity that increased as a function of exposing time (Fig. 3a) . When Pt-NPs derived from hexachloroplatinic acids were incubated with 
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HEp2 cell lysates, they also showed increase in absorption at 220-240 and 260-280 nm in a manner depending upon the dose of cell lysates (Fig. 3b) , demonstrating that the increased absorbance is proportional to the formation of the complex of Pt-NPs and proteins. The emission spectrum was also analyzed, and the results showed in accordance with that of absorption (Fig. 3c) . The mixture of cisplatin with cell lysates was further analyzed by DLS, which measures the size distribution of small particles in suspension. As shown in Fig. 3d , DLS failed to give a readout of the Z-average value with the samples containing either cisplatin alone or the cisplatin mixture with phosphate-buffered saline (PBS) (samples 4 to 6), suggesting that there were no particles generated with cisplatin dissolved in PBS. However, DLS sensed a Z-average value of about 185 nm with the cell lysate alone (sample 7), which could be due to some particle-like structures present in cell lysates. Under the same condition, DLS detected significantly greater Z-average values that range from 205 to 210 nm in samples mixed with cisplatin and different amounts of cell lysates (samples 1-3). The discrepancies (20-25 nm) between the mixtures and the cell lysate alone likely reflected the hydrodynamic size of particles generated from cisplatin, and were consistent with those revealed by TEM (Figs 2 and 4a), which estimated sizes of particles generally less than those obtained by DLS.
To determine whether the cisplatin-derived nanoparticles were made of elemental platinum, the lattice spacing of these nanoparticles was characterized by TEM at high resolutions. The particles in cisplatin-treated HEp2 cells after lysis had a lattice spacing of about 0.25 nm (Fig. 4a) , which is consistent with the distance between platinum atoms in platinum crystals and in Pt-NPs [32, 33] . The similar lattice spacing was also found in the particles present in the HEp2 
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cell lysates mixed with cisplatin ( Fig. 4b) , indicating that those particles are platinum nanoparticles.
To search further evidence that nanoparticles in cisplatin-treated cells were formed by a reducing reaction within cells, cisplatin was incubated for 12 h with several well-characterized cell-associated reducing agents, including nicotinamide adenine dinucleotide phosphate (NA-DPH) (Fig. 4c) , GSH (Fig. 4d) , ascorbic acids (Fig. 4e) and polynucleotides ( Fig. 4f) , respectively. In all these cases, nanoparticles were formed and displayed lattice spacing from 0.24 to 0.25 nm, demonstrating that Pt-NPs generated by these reducing agents have the same atomic feature as those generated within cisplatin treated cells. GSH induced particles from incubation together with cisplatin were also examined under scanning electron microscope (SEM) (Supplementary information, Fig. S1a ) after collected by dialysis and concentration. Energy-dispersive X-ray spectroscopy (EDS) data confirmed these particles contain platinum element (Fig. S1b) .
Role of Pt-NPs formation in cisplatin resistance
Cisplatin is known to be potent in inhibiting the growth of tumor cells by triggering apoptosis [11] [12] [13] [14] . In contrast, the cytotoxicity of Pt-NPs is quite limited [34] [35] [36] [37] [38] [39] [40] . Therefore, the conversion of internalized cisplatin molecules into Pt-NPs within cells might have contributed to the apparent drug resistance with tumor cells, which often express high levels of antioxidant enzymes such as GST [22] [23] [24] . To test this possibility, we examined FaDu, a human pharyngeal carcinoma cell line that was reported to have a relatively higher total cellular GSH as well as a relatively high level of GST expression [23] . Indeed, FaDu cells displayed a better tolerance to cisplatin than did HEp2 cells and remained nearly 50% cell viability when treated with the drug at 16 μg/mL (Fig. 5b) . At the same concentration, few HEp2 cells survived (Fig. 5a ). For both types of cells, synthesized Pt-NPs failed to impose any significant toxicity at concentrations as high as 16 μg/mL, confirming that Pt-NPs are generally not cytostatic. To verify whether the apparent cisplatin-tolerance of FaDu cells is correlated with the formation of Pt-NPs, the absorbance of cell lysates was measured under UV spectrum. As shown in Fig. 6a , the lysates derived from FaDu cells after cisplatin treatment produced a higher absorbance at 260 nm than did HEp2 
CONCLUSION
The pharmacological activity of cisplatin is centered on its ability to target the genomic DNA in the nucleus and subsequently trigger apoptotic programs in the treated cancer cells. Therefore, disruption of any intracellular pathways for internalized cisplatin to translocate into the nucleus would likely contribute to the progression of compromise in drug efficacy or pre-target resistances. One of the plausible mechanisms for the pre-target resistance is the increased detoxification mediated by reducing reagents such as GSH [22, 23] . Part of the reason for GSH to mediate detoxification may involve its nucleophilic property that scavenges the activity of cisplatin. The conjugation of GSH to cisplatin is commonly promoted by GST, an enzyme that is frequently overexpressed in cancer cells [41] [42] [43] . Because glutathione S-conjugates are readily expelled by cells, it is thought that GSH-mediated detoxification is due to increased extrusion of conjugated cisplatin molecules. However, so far there is no clinical evidence yet for the increased release of conjugated cisplatin in resistant cells. We reported here that GSH was able to generate cisplatin-dependent nanoparticles with the similar atomic property as those found in cisplatin treated cells. Although it is unclear at present whether such conversion requires a conjugation between GSH and cisplatin, we found that several other cell-associated reducing agents, including NADPH, ascorbic acids and polynucleotides, were also able to convert cisplatin into nanoparticles similarly as was GSH. This suggests that the conjugation of cisplatin with other molecules such as GSH may not be necessary for the formation of Pt-NPs. We suggest that these particles were formed as a result of reducing reaction itself. To our knowledge, this would be the first report about the presence of Pt-NPs in cisplatin-treated cells. Since Pt-NPs have demonstrated low toxicity and antioxidants are prevalent in cells, our finding offers an alternative explanation for the high incidence of cisplatin resistance. Our finding also challenges a view for the benefit of using antioxidants in cancer therapies, and may provide an opportunity to develop new strategies to circumvent cisplatin resistance. In particular, we found that Pt-NPs formed within cisplatin-treated cells were able to produce a specific absorption under UV light (Fig. 7) . Such property may be exploited to develop new nano-probes for tumor imaging, meaning that the drug resistance developed during cisplatin-based chemotherapies may be readily tracked by following the change in the optical property of treated tumors.
EXPERIMENTAL SECTION Materials
All chemicals except for those mentioned elsewhere were purchased from Sigma. Cisplatin was from Chia-tai Tianqing Pharmaceutical. Anti-GST antibody was from Bioss. Anti-α-tubulin antibody was from KeyGen.
Cell culture
HEp2 cell line was a gift from Jiangsu Cancer Hospital. FaDu cells were from the Cell Bank of Chinese Academy of Sciences. HEp2 cells were cultured in RPMI 1640 medium (Gibco) supplemented with 10% (v/v) fetal ovine serum (FBS), 100 μg/mL streptomycin and 100 units/mL penicillin (Gibco) at 37°C, under air/5% CO 2 mixture atmosphere. FaDu cells were maintained in Minimum Essential Medium (MEM, Hyclone) supplemented with 10% FBS.
Electron microscopy Cells were treated with or without 0.5 μg/mL cisplatin for 
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24 h. 10 7 treated cells were harvested and fixed overnight in PBS containing 2.5% glutaraldehyde at 4℃. The samples were then treated with 1% osmium tetroxide followed by dehydration in ethanol and embedding in Epon (Fluka). The fixed samples were used to generate ultrathin sections (60-80 nm), which were subsequently double stained with uranyl acetate and lead citrate. The stained samples (for lysates and mixtures examined under high-resolution, staining was not needed) were examined by TEM (JEOL/ JEM-2000E). For SEM and EDS, the mixture containing cisplatin and GSH was concentrated by dialysis and evaporation after incubation, and then examined under a Carl Zeiss ULTRA plus field emission scanning electron microscope with supporting by a slice of aluminum foil.
Preparation of platinum nanoparticles
Platinum nanoparticles (Pt-NPs) were prepared as described previously [31, 44] .
Spectrometry
Cells were treated with or without cisplatin as above. The treated cells were suspended in PBS and lysed by sonication. The lysates were analyzed for absorbance at 200-400 nm using UV-3600 spectrophotometer (Shimadzu). In some experiments, cell lysates were mixed with cisplatin or synthesized Pt-NPs prior to spectrometric analysis.
Immunoblotting analysis
Cells were collected by trypsinization followed by centrifugation at 200×g. The pellet of 6×10 6 cells was lysed in 10 μL 6×SDS sample buffer, heated at 95°C for 10 min and separated by SDS-polyacrylamide electrophoresis at 108 V for 80 min. The proteins in the gel were transferred to a polyvinylidene fluoride membrane in buffer containing 25 mM Tris, 192 mM glycine, and 20% methanol. Non-specific binding sites on the membrane were blocked by incubation with 5% bovine serum albumin in TBST (100 mM TrisHCl, pH 7.5, 150 mM NaCl, and 0.05% (v/v) Tween20) at room temperature for 30 min. The membrane was then incubated with anti-GST or anti-α-tubulin antibody at dilutions from 1:200 to 1:1000 in the blocking solution for overnight at 4°C. The membrane was washed three times with TBST followed by incubating for 30 min with the blocking buffer containing horseradish peroxidase-conjugated secondary antibody at 1:1000 to 1:5000 dilutions. The antibody-reactive substances on the membrane were detected by Super Chemiluminescence Development Kit (KeyGen).
Cell viability assay
The cell viability was tested with Cell Counting Kit-8 (CCK-8, KeyGen). Briefly, cells were seeded in 96-well plates at the density of 3×10 3 cells/well and incubated in freshly prepared growth medium supplemented with 10% FBS, 100 μg/mL streptomycin and 100 units/mL penicillin at 37°C and 5% CO 2 . After 24 h, the medium was replaced with the growth medium containing a gradient cisplatin or Pt-NPs in the range from 0 to 50 μg/mL. After incubation for 24 to 72 h, the medium was removed to a new plate, and the cells were rinsed once with PBS and then subjected to CCK-8 analysis. 
